[1]
. Protease Inhibitors (HIV). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():
[PubMed PMID: 31644200]
[2]
Su CT, Ling WL, Lua WH, Haw YX, Gan SK. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance. BMC bioinformatics. 2016 Dec 22:17(Suppl 19):500. doi: 10.1186/s12859-016-1372-3. Epub 2016 Dec 22
[PubMed PMID: 28155724]
[3]
Lee A, Saito E, Ekins S, McMurtray A. Extracellular binding of indinavir to matrix metalloproteinase-2 and the alpha-7-nicotinic acetylcholine receptor: implications for use in cancer treatment. Heliyon. 2019 Sep:5(9):e02526. doi: 10.1016/j.heliyon.2019.e02526. Epub 2019 Sep 30
[PubMed PMID: 31687607]
[4]
Sharma S, Baksi R, Agarwal M. Repositioning of anti-viral drugs as therapy for cervical cancer. Pharmacological reports : PR. 2016 Oct:68(5):983-9. doi: 10.1016/j.pharep.2016.05.007. Epub 2016 Jul 2
[PubMed PMID: 27379616]
[5]
Qiu Y, Maione F, Capano S, Meda C, Picconi O, Brundu S, Pisacane A, Sapino A, Palladino C, Barillari G, Monini P, Bussolino F, Ensoli B, Sgadari C, Giraudo E. HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction. Molecular cancer therapeutics. 2020 Dec:19(12):2476-2489. doi: 10.1158/1535-7163.MCT-20-0055. Epub 2020 Oct 20
[PubMed PMID: 33082275]
Level 2 (mid-level) evidence
[6]
Leonis G, Steinbrecher T, Papadopoulos MG. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study. Journal of chemical information and modeling. 2013 Aug 26:53(8):2141-53. doi: 10.1021/ci4002102. Epub 2013 Jul 24
[PubMed PMID: 23834142]
Level 1 (high-level) evidence
[7]
Su CT, Koh DW, Gan SK. Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs. Molecules (Basel, Switzerland). 2019 Sep 6:24(18):. doi: 10.3390/molecules24183243. Epub 2019 Sep 6
[PubMed PMID: 31489889]
[8]
Aarnoutse RE, Wasmuth JC, Fätkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P, Hekster YA, Burger DM, Rockstroh JK. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antiviral therapy. 2003 Aug:8(4):309-14
[PubMed PMID: 14518700]
[9]
Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. The New England journal of medicine. 1997 Sep 11:337(11):734-9
[PubMed PMID: 9287228]
[10]
Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs. 1999 Dec:58(6):1165-203
[PubMed PMID: 10651394]
[11]
Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology: Indinavir Nephrotoxicity. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017 Jan:69(1):e3. doi: 10.1053/j.ajkd.2016.11.004. Epub
[PubMed PMID: 28007196]
[12]
Powis KM, Huo Y, Williams PL, Kacanek D, Jao J, Patel K, Seage GR 3rd, Van Dyke RB, Chadwick EG, Pediatric HIV/AIDS Cohort Study (PHACS). Antiretroviral Prescribing Practices Among Pregnant Women Living With HIV in the United States, 2008-2017. JAMA network open. 2019 Dec 2:2(12):e1917669. doi: 10.1001/jamanetworkopen.2019.17669. Epub 2019 Dec 2
[PubMed PMID: 31851347]
[14]
Matłosz B, Pietraszkiewicz E, Firląg-Burkacka E, Grycner E, Horban A, Kowalska JD. Risk factors for kidney disease among HIV-1 positive persons in the methadone program. Clinical and experimental nephrology. 2019 Mar:23(3):342-348. doi: 10.1007/s10157-018-1644-5. Epub 2018 Sep 14
[PubMed PMID: 30218298]
[15]
Gupta V, El Ters M, Kashani K, Leung N, Nasr SH. Crystalglobulin-induced nephropathy. Journal of the American Society of Nephrology : JASN. 2015 Mar:26(3):525-9. doi: 10.1681/ASN.2014050509. Epub 2014 Sep 4
[PubMed PMID: 25190731]
[16]
Loens C, Amet S, Isnard-Bagnis C, Deray G, Tourret J. [Nephrotoxicity of antiretrovirals other than tenofovir]. Nephrologie & therapeutique. 2018 Feb:14(1):55-66. doi: 10.1016/j.nephro.2017.12.001. Epub
[PubMed PMID: 29500080]
[17]
Izzedine H, Lescure FX, Bonnet F. HIV medication-based urolithiasis. Clinical kidney journal. 2014 Apr:7(2):121-6. doi: 10.1093/ckj/sfu008. Epub 2014 Mar 11
[PubMed PMID: 25852859]
[19]
Calitz C, Gouws C, Viljoen J, Steenekamp J, Wiesner L, Abay E, Hamman J. Herb-Drug Pharmacokinetic Interactions: Transport and Metabolism of Indinavir in the Presence of Selected Herbal Products. Molecules (Basel, Switzerland). 2015 Dec 10:20(12):22113-27. doi: 10.3390/molecules201219838. Epub 2015 Dec 10
[PubMed PMID: 26690396]
[20]
Nicolussi S, Drewe J, Butterweck V, Meyer Zu Schwabedissen HE. Clinical relevance of St. John's wort drug interactions revisited. British journal of pharmacology. 2020 Mar:177(6):1212-1226. doi: 10.1111/bph.14936. Epub 2020 Jan 17
[PubMed PMID: 31742659]
[21]
Tian DD, Leonowens C, Cox EJ, González-Pérez V, Frederick KS, Scarlett YV, Fisher MB, Paine MF. Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. Drug metabolism and disposition: the biological fate of chemicals. 2019 Jul:47(7):724-731. doi: 10.1124/dmd.119.087007. Epub 2019 Apr 26
[PubMed PMID: 31028057]
[22]
Hortin GL, King C, Miller KD, Kopp JB. Detection of indinavir crystals in urine: dependence on method of analysis. Archives of pathology & laboratory medicine. 2000 Feb:124(2):246-50
[PubMed PMID: 10656734]
[23]
Goldschmidt R, Chu C. HIV Infection in Adults: Initial Management. American family physician. 2021 Apr 1:103(7):407-416
[PubMed PMID: 33788514]
[24]
Lehman HP, Benson JO, Beninger PR, Anderson CA, Blumenthal SJ, Sharrar RG. A five-year evaluation of reports of overdose with indinavir sulfate. Pharmacoepidemiology and drug safety. 2003 Sep:12(6):449-57
[PubMed PMID: 14513658]
[25]
Burkhart KK, Kemerer K, Donovan JW. Indinavir overdose. Journal of toxicology. Clinical toxicology. 1998:36(7):747
[PubMed PMID: 9865247]
[26]
Pinto RM, Kay ES, Choi CJ, Wall MM. Interprofessional collaboration improves linkages to primary care: a longitudinal analysis. AIDS care. 2020 Aug:32(8):970-978. doi: 10.1080/09540121.2019.1668537. Epub 2019 Sep 17
[PubMed PMID: 31530005]